Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by PepGen Inc.
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
October 02, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
September 26, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Pricing of $100 Million Public Offering
September 24, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Proposed Public Offering
September 24, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
September 24, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 07, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
May 28, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
May 20, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 08, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
April 02, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Appointment of Two New Directors to its Board
March 31, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 10, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen to Participate in Upcoming Investor Conferences
March 04, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
March 04, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
February 24, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
February 24, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces CONNECT Program Updates
January 29, 2025
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
December 16, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
November 21, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 07, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen to Participate in Upcoming Investor Conferences
November 04, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
October 08, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
September 19, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
August 20, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
August 20, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 30, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 02, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Announces Executive Team Promotions
June 11, 2024
From
PepGen Inc.
Via
Business Wire
Tickers
PEPG
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
PepGen Inc.
Via
GlobeNewswire
Tickers
PEPG
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today